Long-term study of K-877 add-on to HMG-CoA reductase inhibitor in patients with dyslipidemia

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222021

Enrollment

400

Registered

2013-02-14

Start date

2013-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

investigational material(s) Generic name etc : K-877 INN of investigational material : Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Dyslipidemia with high TG in treatment with HMG-CoA reductase inhibitor

Exclusion criteria

Exclusion criteria: Person who has severe liver disease

Design outcomes

Primary

Measure	Time frame
TG percent change at the completion of treatment Central laboratory test	—

Secondary

Measure	Time frame
Percent changes of other lipid parameters at the completion of treatment Central laboratory test	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026